ARTICLE | Clinical News
Praecis, Amgen to start abarelix Phase IIIb
June 4, 2001 7:00 AM UTC
PRCS and partner AMGN will begin U.S. Phase IIIb testing of their abarelix depot LHRH/GnRH antagonist to treat prostate cancer. Patients in the 15-month trial will receive abarelix or Lupron leuprolid...